PIK3CA: a Target or a Marker in Breast Cancers

摘要: The phosphoinositide 3 kinase (PI3K)/Akt pathway is frequently aberrantly activated in breast cancer and, basing on preclinical data, leads to cell growth and tumor proliferation. PI3K activation has been suggested as a potential driver of resistance endocrine anti-HER2 therapies. Large genomic studies have observed that the PIK3CA gene mutated up 40 % cancers, mainly estrogen receptor- HER2-positive. Some strategies targeting PI3K/Akt/mTOR axis, particular co-targeting receptor mTOR resistant receptor-positive cancer, proven successfully this hypothesis. Pan-class I inhibitors more selective p110α are currently under investigation different clinical settings. In review, data prognostic predictive role mutations subtypes covered, picture current research provided.